Real-life management of dual antiplatelet therapy after percutaneous coronary intervention: insights from the French national registry (France-PCI)
Project summary
CONTEXT
Dual anti-platelet aggregation (DAPT) remains the cornerstone of treatment pharmacological treatment after percutaneous revascularization for acute coronary syndrome (ACS) or chronic coronary syndrome. The standard recommended duration for revascularization for stable angina is 3 to 6 months and up to 12 months after ACS without a high risk of bleeding. Following the development of latest generation active stents, shorter DAPT with early aspirin monotherapy has become possible leading to a reduction in bleeding events without an increase in ischemic events. Early monotherapy with a P2Y12 receptor inhibitor from 1 to 3 months post-angioplasty has also been demonstrated
feasible in cases of high hemorrhagic and ischemic risk.
It is unclear how these strategies are currently applied in routine practice.
GOALS
The objective of this retrospective study is to take stock of DAPT after coronary angioplasty (with active stent) by focusing on these new short strategies of dual anti-aggregant therapy.
METHODOLOGY
Descriptive analysis of baseline characteristics of patients admitted for coronary angioplasty
scheduled or urgent. Descriptive analysis of double anti-aggregation associations and presence of relays carried out during follow-up.